基本信息:
- 专利标题： COMPANION DIAGNOSTIC ASSAYS FOR CANCER THERAPY
- 专利标题（中）：用于癌症治疗的组合诊断测定
- 申请号：PCT/US2007026526 申请日：2007-12-28
- 公开(公告)号：WO2008082673A2 公开(公告)日：2008-07-10
- 发明人： SEMIZAROV DIMITRI , MCKEEGAN EVELYN M , LESNIEWSKI RICK R , TSE CHRISTIN , WANG GANG
- 申请人： ABBOTT LAB , SEMIZAROV DIMITRI , MCKEEGAN EVELYN M , LESNIEWSKI RICK R , TSE CHRISTIN , WANG GANG
- 专利权人： ABBOTT LAB,SEMIZAROV DIMITRI,MCKEEGAN EVELYN M,LESNIEWSKI RICK R,TSE CHRISTIN,WANG GANG
- 当前专利权人： ABBOTT LAB,SEMIZAROV DIMITRI,MCKEEGAN EVELYN M,LESNIEWSKI RICK R,TSE CHRISTIN,WANG GANG
- 优先权： US64691006 2006-12-28
摘要：
A method for classifying cancer patients as eligible to receive cancer therapy comprising determination of the presence or absence in a patient tissue sample of chromosomal copy number gain at chromosomal locus 18q21-q22. The classification of cancer patients based upon the presence or absence of 18q21-q22 gain allows selection of patients to receive chemotherapy, such as therapy with a Bcl-2 family inhibitor, and for monitoring patient response to therapy.
摘要（中）：
将癌症患者分类为符合接受癌症治疗的方法，包括确定患者组织样品中存在或不存在染色体基因座18q21-q22处染色体拷贝数增益的方法。 基于18q21-q22增益的存在或不存在，癌症患者的分类允许选择接受化疗的患者，例如用Bcl-2家族抑制剂治疗，并监测患者对治疗的反应。
公开/授权文献:
- WO2008082673A3 COMPANION DIAGNOSTIC ASSAYS FOR CANCER THERAPY 公开/授权日：2009-01-22